Identification

Name
Eprosartan
Accession Number
DB00876  (APRD00950)
Type
Small Molecule
Groups
Approved
Description

Eprosartan is an angiotensin II receptor antagonist used for the treatment of high blood pressure. It acts on the renin-angiotensin system in two ways to decrease total peripheral resistance. First, it blocks the binding of angiotensin II to AT1 receptors in vascular smooth muscle, causing vascular dilatation. Second, it inhibits sympathetic norepinephrine production, further reducing blood pressure.

Structure
Thumb
Synonyms
  • (e)-2-Butyl-1-(P-carboxybenzyl)-alpha-2-thenylimidazole-5-acrylic acid
  • (e)-3-[2-N-Butyl-1-{(4-carboxyphenyl)methyl}-1H-imidazol-5-yl]-2-(2-thienyl)methyl-2-propenoic acid
  • (e)-Alpha{[2-butyl-1-[(4-carboxyphenyl)methyl]-1H-imidazole-5-yl]methylene}-2-thiopheneproprionic acid
  • Éprosartan
  • Eprosartan
  • Eprosartanum
External IDs
SK&F-108566 / SKF 108566
Product Ingredients
IngredientUNIICASInChI Key
Eprosartan mesylate8N2L1NX8S3144143-96-4DJSLTDBPKHORNY-XMMWENQYSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
TevetenTablet400 mg/1OralPhysicians Total Care, Inc.2003-04-302008-09-30Us
TevetenTablet600 mg/1OralAbbvie2010-05-242015-06-18Us00074 3040 11 nlmimage10 db1d6dfb
TevetenTablet600 mgOralBgp Pharma Ulc2001-05-25Not applicableCanada
TevetenTablet600 mg/1OralKos Pharmaceuticals, Inc.2007-02-202007-02-20Us
TevetenTablet400 mg/1OralAbbvie2010-05-242013-10-12Us
TevetenTablet400 mgOralBgp Pharma Ulc2000-09-08Not applicableCanada
TevetenTablet400 mg/1OralKos Pharmaceuticals, Inc.2007-02-202007-02-20Us
Teveten Tablets 300 mgTablet300 mgOralSolvay Pharma Inc2000-09-082003-01-02Canada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Eprosartan MesylateTablet, film coated600 mg/1OralMylan Pharmaceuticals2011-12-20Not applicableUs
Eprosartan MesylateTablet, film coated400 mg/1OralMylan Pharmaceuticals Inc.2011-11-162011-06-15Us
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralAbbvie2010-05-242015-06-29Us
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralKos Pharmaceuticals, Inc.2007-01-202007-01-20Us
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralPhysicians Total Care, Inc.2005-05-06Not applicableUs
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralAbbvie2010-05-242015-08-22Us00074 3020 11 nlmimage10 e01d703b
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralPhysicians Total Care, Inc.2005-04-252011-06-30Us
Teveten HCTEprosartan mesylate (600 mg/1) + Hydrochlorothiazide (25 mg/1)TabletOralKos Pharmaceuticals, Inc.2007-01-202007-01-20Us
Teveten PlusEprosartan (600 mg) + Hydrochlorothiazide (12.5 mg)TabletOralBgp Pharma Ulc2004-07-06Not applicableCanada
International/Other Brands
Eprozar (INTAS Pharmaceuticals) / Futuran (Merck)
Categories
UNII
2KH13Z0S0Y
CAS number
133040-01-4
Weight
Average: 424.513
Monoisotopic: 424.145677956
Chemical Formula
C23H24N2O4S
InChI Key
OROAFUQRIXKEMV-LDADJPATSA-N
InChI
InChI=1S/C23H24N2O4S/c1-2-3-6-21-24-14-19(12-18(23(28)29)13-20-5-4-11-30-20)25(21)15-16-7-9-17(10-8-16)22(26)27/h4-5,7-12,14H,2-3,6,13,15H2,1H3,(H,26,27)(H,28,29)/b18-12+
IUPAC Name
4-({2-butyl-5-[(1E)-2-carboxy-2-(thiophen-2-ylmethyl)eth-1-en-1-yl]-1H-imidazol-1-yl}methyl)benzoic acid
SMILES
CCCCC1=NC=C(\C=C(/CC2=CC=CS2)C(O)=O)N1CC1=CC=C(C=C1)C(O)=O

Pharmacology

Indication

For the management of hypertension alone or in combination with other classes of antihypertensive agents. Also used as a first-line agent in the treatment of diabetic nephropathy, as well as a second-line agent in the treatment of congestive heart failure (only in those intolerant of ACE inhibitors).

Associated Conditions
Pharmacodynamics

Angiotensin II, the principal pressor agent of the renin-angiotensin system, is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme [kininase II]. It is responsible for effects such as vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Eprosartan selectively blocks the binding of angiotensin II to the AT1 receptor, which in turn leads to multiple effects including vasodilation, a reduction in the secretion of vasopressin, and reduction in the production and secretion of aldosterone. The resulting effect is a decrease in blood pressure.

Mechanism of action

Eprosartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor found in many tissues (e.g., vascular smooth muscle, adrenal gland). There is also an AT2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis. Eprosartan does not exhibit any partial agonist activity at the AT1 receptor. Its affinity for the AT1 receptor is 1,000 times greater than for the AT2 receptor. In vitro binding studies indicate that eprosartan is a reversible, competitive inhibitor of the AT1 receptor. Eprosartan has also been shown to bind to AT1 receptors both presynaptically and synaptically. Its action on presynaptic AT1 receptors results in the inhibition of sympathetically stimulated noradrenaline release. Unlike ACE inhibitors, eprosartan and other ARBs do not interfere with response to bradykinins and substance P, which allows for the absence of adverse effects that are present in ACE inhibitors (eg. dry cough).

TargetActionsOrganism
AType-1 angiotensin II receptor
antagonist
Human
Absorption

Absolute bioavailability following a single 300 mg oral dose of eprosartan is approximately 13%. Administering eprosartan with food delays absorption.

Volume of distribution
Not Available
Protein binding

Plasma protein binding of eprosartan is high (approximately 98%) and constant over the concentration range achieved with therapeutic doses.

Metabolism

Eprosartan is not metabolized by the cytochrome P450 system. It is mainly eliminated as unchanged drug. Less than 2% of an oral dose is excreted in the urine as a glucuronide.

Route of elimination
Not Available
Half life

The terminal elimination half-life of eprosartan following oral administration is typically 5 to 9 hours.

Clearance
Not Available
Toxicity

There was no mortality in rats and mice receiving oral doses of up to 3000 mg eprosartan/kg and in dogs receiving oral doses of up to 1000 mg eprosartan/kg.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Eprosartan Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
AcebutololEprosartan may increase the hypotensive activities of Acebutolol.
AceclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Aceclofenac.
AcemetacinThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Acetylsalicylic acid.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Eprosartan is combined with Acipimox.
AgmatineThe risk or severity of hyperkalemia can be increased when Eprosartan is combined with Agmatine.
AlclofenacThe risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Eprosartan is combined with Alclofenac.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Eprosartan.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Eprosartan.
AlfuzosinAlfuzosin may increase the hypotensive activities of Eprosartan.
Food Interactions
  • Take without regard to meals.

References

Synthesis Reference

Richard T. Matsuoka, Peng Liu, "Process for preparing eprosartan using regioselective protection of 2,4-disubstituted-imidazole intermediates." U.S. Patent US6294675, issued June, 1992.

US6294675
General References
  1. Ruilope L, Jager B, Prichard B: Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press. 2001;10(4):223-9. [PubMed:11800061]
  2. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062]
  3. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389]
  4. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247]
  5. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407]
  6. Blankestijn PJ, Rupp H: Clinical profile of eprosartan: a different angiotensin II receptor blocker. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. [PubMed:18855637]
External Links
Human Metabolome Database
HMDB0015014
KEGG Drug
D04040
KEGG Compound
C07467
PubChem Compound
5281037
PubChem Substance
46506765
ChemSpider
4444504
BindingDB
50011977
ChEBI
4814
ChEMBL
CHEMBL813
Therapeutic Targets Database
DAP001367
PharmGKB
PA449481
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
PDRhealth
PDRhealth Drug Page
Wikipedia
Eprosartan
ATC Codes
C09CA02 — EprosartanC09DA02 — Eprosartan and diuretics
AHFS Codes
  • 24:32.08 — Angiotensin Ii Receptor Antagonists
FDA label
Download (1.09 MB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedNot AvailableKidney Diseases1
3CompletedTreatmentHypertension,Essential1
4CompletedNot AvailableHealthy Volunteers1
4CompletedNot AvailableHypertension,Essential1
Not AvailableCompletedTreatmentHigh Blood Pressure (Hypertension) / Type 2 Diabetes Mellitus1

Pharmacoeconomics

Manufacturers
  • Abbott laboratories
Packagers
  • Abbott Laboratories Ltd.
  • BTA Pharmaceuticals
  • Irvs Pharmacy and Sickroom Supply
  • Physicians Total Care Inc.
  • Solvay Pharmaceuticals
Dosage forms
FormRouteStrength
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral600 mg/1
TabletOral400 mg
TabletOral400 mg/1
TabletOral600 mg/1
TabletOral600 mg
TabletOral
TabletOral300 mg
Prices
Unit descriptionCostUnit
Teveten hct 600-12.5 mg tablet3.52USD tablet
Teveten hct 600-25 mg tablet3.42USD tablet
Teveten 600 mg tablet3.19USD tablet
Teveten 400 mg tablet2.83USD tablet
Teveten 400 mg tiltab1.24USD tablet
Teveten 600 mg Tablet1.18USD tablet
Teveten 400 mg Tablet0.79USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5656650No1994-08-122014-08-12Us
US5185351No1993-02-092010-02-09Us
CA2250395No2005-09-062017-03-26Canada
CA2115170No2004-05-252012-08-12Canada

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)248-250 °C (mesylate form)Not Available
water solubilityInsoluble (mesylate form)Not Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00866 mg/mLALOGPS
logP3.57ALOGPS
logP3.8ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)3.63ChemAxon
pKa (Strongest Basic)6.93ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area92.42 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity117.02 m3·mol-1ChemAxon
Polarizability45.29 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9863
Blood Brain Barrier-0.6931
Caco-2 permeable-0.6261
P-glycoprotein substrateSubstrate0.8011
P-glycoprotein inhibitor INon-inhibitor0.8577
P-glycoprotein inhibitor IINon-inhibitor0.9574
Renal organic cation transporterNon-inhibitor0.7673
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateNon-substrate0.7557
CYP450 1A2 substrateNon-inhibitor0.5798
CYP450 2C9 inhibitorNon-inhibitor0.6617
CYP450 2D6 inhibitorNon-inhibitor0.8325
CYP450 2C19 inhibitorNon-inhibitor0.6234
CYP450 3A4 inhibitorNon-inhibitor0.6086
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.644
Ames testNon AMES toxic0.7313
CarcinogenicityNon-carcinogens0.9454
BiodegradationNot ready biodegradable0.6117
Rat acute toxicity2.4288 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9464
hERG inhibition (predictor II)Non-inhibitor0.8827
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0009000000-fa421ee23b907968b800
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-694c481f9555295f9426
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004u-0289000000-647b9ea41a7a812dea66
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kg-0290000000-08e189bdaeb9c6af3b4f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014j-1290000000-e8207e65f017389d706f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00lr-9260000000-7b844b75045cf89e145e
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9100000000-f49fc8384f38dc7b6e3b
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0002900000-e62e6d74d830487d0954
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-002u-0198000000-d571b7bcdbe9e3f7e69f
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00kp-0290000000-0b7c3fe664812ce51596
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-014j-1090000000-85f4ee357273ee0268c0
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9240000000-8ed6c4fadafd173a2579
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-001i-9400000000-81bd0b20c45458b1bdec
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0009000000-0333ac2f95788dceda2c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-0196300000-c2476723863e5584d7e8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-a93af7ff9cf5786971d0
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-056r-0171900000-4a8d34412967af4cbf35
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1971000000-ee85641cdce897ab6693
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1920000000-282ecc38e7c0c6cbefef
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-1a109162fa90e4ce7932
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-2900000000-54946c90c1dfdf5eb21e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-004i-0000900000-f33c4c2419ad566fa726
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-056r-1172900000-e0852717bfa6c5f8f0cd
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1970000000-fed4d418faa53031f6ca
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-052r-1920000000-2ddeec1f39e95c27109d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4r-1910000000-2953fc7d89567648d5ea
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4i-1900000000-1e52f8edbad114f026d5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0a4l-0196300000-e398b1a8add5df82164b

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzoic acids. These are organic Compounds containing a benzene ring which bears at least one carboxyl group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Benzoic acids and derivatives
Direct Parent
Benzoic acids
Alternative Parents
Imidazolyl carboxylic acids and derivatives / Benzoyl derivatives / 1,2,5-trisubstituted imidazoles / N-substituted imidazoles / Dicarboxylic acids and derivatives / Thiophenes / Heteroaromatic compounds / Carboxylic acids / Azacyclic compounds / Organopnictogen compounds
show 4 more
Substituents
Benzoic acid / 1,2,5-trisubstituted-imidazole / Benzoyl / Imidazolyl carboxylic acid derivative / Trisubstituted imidazole / Dicarboxylic acid or derivatives / N-substituted imidazole / Azole / Heteroaromatic compound / Imidazole
show 14 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
imidazoles, thiophenes, dicarboxylic acid (CHEBI:4814)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
Receptor for angiotensin II. Mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system.
Gene Name
AGTR1
Uniprot ID
P30556
Uniprot Name
Type-1 angiotensin II receptor
Molecular Weight
41060.53 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  2. Heusser K, Vitkovsky J, Schmieder RE, Schobel HP: AT1 antagonism by eprosartan lowers heart rate variability and baroreflex gain. Auton Neurosci. 2003 Aug 29;107(1):45-51. [PubMed:12927226]
  3. Gremmler B, Kunert M, Schleiting H, Ulbricht LJ: Improvement of cardiac output in patients with severe heart failure by use of ACE-inhibitors combined with the AT1-antagonist eprosartan. Eur J Heart Fail. 2000 Jun;2(2):183-7. [PubMed:10856732]
  4. Suzuki G, Mishima T, Tanhehco EJ, Sharov VG, Todor A, Rostogi S, Gupta RC, Chaudhry PA, Anagnostopoulos PV, Nass O, Goldstein S, Sabbah HN: Effects of the AT1-receptor antagonist eprosartan on the progression of left ventricular dysfunction in dogs with heart failure. Br J Pharmacol. 2003 Jan;138(2):301-9. [PubMed:12540520]
  5. Ilson BE, Martin DE, Boike SC, Jorkasky DK: The effects of eprosartan, an angiotensin II AT1 receptor antagonist, on uric acid excretion in patients with mild to moderate essential hypertension. J Clin Pharmacol. 1998 May;38(5):437-41. [PubMed:9602957]
  6. Nap A, Mathy MJ, Balt JC, Pfaffendorf M, van Zwieten PA: Pre- and postsynaptic inhibitory potencies of the angiotensin AT1 receptor antagonists eprosartan and candesartan. Eur J Pharmacol. 2003 May 23;469(1-3):117-24. [PubMed:12782193]
  7. Hedner T: The clinical profile of the angiotensin II receptor blocker eprosartan. J Hypertens Suppl. 2002 Jun;20(5):S33-8. [PubMed:12184062]
  8. Puig JG, Lopez MA, Bueso TS, Bernardino JI, Jimenez RT: Clinical profile of eprosartan. Cardiovasc Drugs Ther. 2002 Dec;16(6):543-9. [PubMed:12766389]
  9. Ruilope L, Jager B: Eprosartan for the treatment of hypertension. Expert Opin Pharmacother. 2003 Jan;4(1):107-14. [PubMed:12517247]
  10. de la Sierra A, Ram CV: Introduction: The pharmacological profile of eprosartan--implications for cerebrovascular and cardiovascular risk reduction. Curr Med Res Opin. 2007 Nov;23 Suppl 5:S1-3. doi: 10.1185/030079907X260692. [PubMed:18093407]
  11. Murdoch DR, McDonagh TA, Farmer R, Morton JJ, McMurray JJ, Dargie HJ: ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects. Am Heart J. 2001 May;141(5):800-7. [PubMed:11320369]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Organic anion transmembrane transporter activity
Specific Function
Mediates hepatobiliary excretion of numerous organic anions. May function as a cellular cisplatin transporter.
Gene Name
ABCC2
Uniprot ID
Q92887
Uniprot Name
Canalicular multispecific organic anion transporter 1
Molecular Weight
174205.64 Da
References
  1. Weiss J, Sauer A, Divac N, Herzog M, Schwedhelm E, Boger RH, Haefeli WE, Benndorf RA: Interaction of angiotensin receptor type 1 blockers with ATP-binding cassette transporters. Biopharm Drug Dispos. 2010 Mar;31(2-3):150-61. doi: 10.1002/bdd.699. [PubMed:20222053]

Drug created on June 13, 2005 07:24 / Updated on October 18, 2018 14:56